PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

NCT02326168 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Bacillus Calmette-Guerin (BCG)

Sponsor

The University of Texas Health Science Center at San Antonio